Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996913 | 0.91 | ALDH1A1 (0.41) | ENPP2PSMB5P2RX7MAPTLMNA | |
| SCHEMBL4990060 | 0.90 | ALDH1A1 (0.41) | METAP2ENPP2PTGDR2PSMB5P2RX7 | |
| SCHEMBL4999246 | 0.90 | METAP2 (0.42) | METAP2ENPP2PTGDR2POLBMAPT | |
| SCHEMBL4780847 | 0.88 | PSMB5 (0.37) | METAP2ENPP2PTGDR2PSMB5LMNA | |
| SCHEMBL4995223 | 0.88 | ALDH1A1 (0.47) | ENPP2PTGDR2MAPTLMNANPC1 | |
| SCHEMBL4725811 | 0.87 | KMT2A (0.38) | METAP2ENPP2PTGDR2PSMB5MAPT | |
| SCHEMBL14092541 | 0.87 | KMT2A (0.42) | METAP2ENPP2PTGDR2PSMB5P2RX7 | |
| SCHEMBL14092508 | 0.86 | GNRHR (0.41) | METAP2ENPP2PTGDR2MAPTLMNA | |
| SCHEMBL14092506 | 0.86 | MAPT (0.43) | METAP2ENPP2PTGDR2POLBMAPT | |
| SCHEMBL4727507 | 0.86 | MAPT (0.41) | METAP2PTGDR2MAPTLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | METAP2 967/4885ENPP2 398/4885PTGDR2 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.